Lars Jørgen Østergaard

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. / Jakobsen, Martin Roelsgaard; Arildsen, Hanne; Krarup, Henrik B; Tolstrup, Martin; Østergaard, Lars; Laursen, Alex L.

In: Clinical Infectious Diseases, Vol. 46, No. 9, 2008, p. e88-91.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{18f5b9908a1b11ddbd84000ea68e967b,
title = "Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.",
abstract = "Recently, entecavir was introduced as a potent drug against hepatitis B virus infection. Initially, it was suggested not to have any effect on human immunodeficiency virus (HIV) infection. This guideline was revised in 2007 because of a report showing that the M184V mutation was selected in an hepatitis B virus and HIV-coinfected patient previously treated with lamivudine. Our investigation revealed findings similar to those preveiously reported but in an antiretroviral therapy-naive patient coinfected with HIV and hepatitis B virus. After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection.",
keywords = "Aged, Anti-HIV Agents, Guanine, HIV Infections, HIV Reverse Transcriptase, Humans, Male, Mutation, Phylogeny, env Gene Products, Human Immunodeficiency Virus",
author = "Jakobsen, {Martin Roelsgaard} and Hanne Arildsen and Krarup, {Henrik B} and Martin Tolstrup and Lars {\O}stergaard and Laursen, {Alex L}",
year = "2008",
doi = "10.1086/587174",
language = "English",
volume = "46",
pages = "e88--91",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.

AU - Jakobsen, Martin Roelsgaard

AU - Arildsen, Hanne

AU - Krarup, Henrik B

AU - Tolstrup, Martin

AU - Østergaard, Lars

AU - Laursen, Alex L

PY - 2008

Y1 - 2008

N2 - Recently, entecavir was introduced as a potent drug against hepatitis B virus infection. Initially, it was suggested not to have any effect on human immunodeficiency virus (HIV) infection. This guideline was revised in 2007 because of a report showing that the M184V mutation was selected in an hepatitis B virus and HIV-coinfected patient previously treated with lamivudine. Our investigation revealed findings similar to those preveiously reported but in an antiretroviral therapy-naive patient coinfected with HIV and hepatitis B virus. After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection.

AB - Recently, entecavir was introduced as a potent drug against hepatitis B virus infection. Initially, it was suggested not to have any effect on human immunodeficiency virus (HIV) infection. This guideline was revised in 2007 because of a report showing that the M184V mutation was selected in an hepatitis B virus and HIV-coinfected patient previously treated with lamivudine. Our investigation revealed findings similar to those preveiously reported but in an antiretroviral therapy-naive patient coinfected with HIV and hepatitis B virus. After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection.

KW - Aged

KW - Anti-HIV Agents

KW - Guanine

KW - HIV Infections

KW - HIV Reverse Transcriptase

KW - Humans

KW - Male

KW - Mutation

KW - Phylogeny

KW - env Gene Products, Human Immunodeficiency Virus

U2 - 10.1086/587174

DO - 10.1086/587174

M3 - Journal article

C2 - 18419429

VL - 46

SP - e88-91

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -